潘崢嬰，現為北京大學深圳研究生院博士生導師，特聘研究員。
其課題組致力於開拓新的方法用於研究人類化學生物學及推動藥物的發現。我們結合尖端的藥物化學和新興化學蛋白質組學推進我們對疾病的認識和發現新的治療藥物。最初的成果包括：被譽為 “突破”的首創新藥已批准在美國和歐盟上市，以及人類樣品中活細胞成像和套用的小分子探針。超過20項的國際專利及專利申請。
基本介紹
- 中文名：潘崢嬰
- 畢業院校：哥倫比亞大學
- 學位/學歷：博士
- 職業：教師
- 專業方向：腫瘤導向性的藥物化學、激酶組學、發展合成方法學
- 職務：課題組長
- 職稱：特聘研究員
個人經歷,代表作品,榮譽獎勵,
個人經歷
2009-至今，北京大學深圳研究生院，深圳，博士生導師，特聘研究員
2008-2009，OPTI Medical Systems, IDEXX 實驗室，Roswell，
2006-2007， AtheroGenics, Alpharetta，高級科學家
2002-2006， Celera Genomics, South San Francisco，高級科學家
2000-2002，史丹福大學，斯坦福，博士後
1994-1999，哥倫比亞大學，紐約，博士
1989-1994，北京大學，北京，學士
代表作品
- 1. Ding, N.; Li, X.; Shi, Y.; Ping, L.; Wu, L.; Fu, K.; Feng, L.; Zheng, X.; Song, Y.*;Pan, Z. *; Zhu, J.* “Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.”Oncotarget2015, published online Apr 14.2. Zhang Q, Liu H,Pan Z.*“A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells”Chem. Commun.2014,50, 15319.3. Liu H, Yang Z,Pan Z.*“Synthesis of Highly Substituted Imidazolidine-2,4-dione (Hydantoin) through Tf2O-Mediated Dual Activation of Boc-Protected Dipeptidyl Compounds”Org. Lett.2014,16, 5902.4. Zhou Y, Guo T, Tang G, Wu H, Wong N-K,Pan Z.*“Site-selective Protein Immobilization by Covalent Modification of GST Fusion Proteins”Bioconjugate Chem.2014,25, 1911.5. Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N,Pan Z.*“Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity”J. Med. Chem.2014,57, 5112.6. Zhou Y, Guo T, Li X, Dong Y, Galatsis P, Johnson D S,Pan Z.*“Discovery of selective 2,4-diaminopyrimidinebased photoaffinity probes for glyoxalase I”Med. Chem. Commun.2014,5, 352. (Invited for the thematic issue on “Chemical biology for target identification and validation”)7. Zheng J, Lin S, Zhu X, Jiang B*, Yang Z*,Pan Z.*“Reductant-directed formation of PS-PAMAM-supported gold nanoparticles for use as highly active and recyclable catalysts for the aerobic oxidation of alcohols and the homocoupling of phenylboronic acids.”Chem. Commun.2012,48,6235.8. Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.;Pan, Z.;Thamm, D.H.; Miller, R.A.; Buggy, J.J. “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-cell Activation and Is Efficacious in Models of Autoimmune Disease and B-cell Malignancy”Proc. Natl. Acad. Sci. USA2010,107,13075.9. Pan, Z.; Scheerens, H.; Li, S.-J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Peter R. Young, Dalrymple, S. A. and Palmer, J. T. “Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase”ChemMedChem2007,15:58. (corresponding author)10.Pan, Z.; Jeffery, D. A.; Chehade, K.; Beltman, J.; Clark, J. M.; Grothaus, P. G.; Bogyo, M. and Baruch, A. “Development of Activity-based Probes for Trypsin-family Serine Proteases”Bioorg. Med. Chem. Lett.2006,16: 2882. (co-corresponding author)
榮譽獎勵
2013，生命科學與化學學者藥明康德獎，上海
2005 ，Celera DNA Award Celera Genomics, South San Francisco, CA
1994，優秀畢業生獎，北京大學，北京
